[SCHEDULE 13G] ArriVent BioPharma, Inc. SEC Filing

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. is reported as having a significant passive stake held by related Infinitum entities. The filing shows Infinitum Cayman Master Ltd, Infinitum Asset Management LLC and Infinitum Partners GP, LLC each beneficially own 3,418,923 shares, representing 9.99% of the company’s common stock, and each reports sole voting and sole dispositive power over those shares. The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The disclosure identifies the three reporting entities as the holders and confirms the position is a material passive stake.

Insights

Securities Analyst

TL;DR: Infinitum reports a material 9.99% passive position with sole voting/dispositive power; filing signals notable ownership without an intent to seek control.

The Form 13G shows a single beneficial position of 3,418,923 shares (9.99%) held through affiliated entities with sole voting and dispositive authority. From an investor-analytics perspective this is material ownership that could influence market perception but the filer explicitly certifies the stake is held in the ordinary course and not to change control. The filing does not disclose transaction dates, cost basis or any plans to alter the position.

Corporate Governance Expert

TL;DR: A near-10% stake with sole voting/dispositive power merits governance monitoring; no active control intent declared by the filer.

The report names three related reporting persons and attributes sole voting and dispositive power to each over the same block of 3,418,923 shares (9.99%). The certification states the holdings were not acquired to change or influence control, which classifies this as a passive disclosure under Schedule 13G. For governance teams, the position is material and should be noted, but the filing provides no indication of activism or planned board engagement.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ArriVent BioPharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04272N102

(CUSIP Number)

05/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

INFINITUM ASSET MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,418,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,418,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,418,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

Infinitum Cayman Master, Ltd. (Fund)

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,418,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,418,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,418,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

Infinitum Partners GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,418,923.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,418,923.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,418,923.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ArriVent BioPharma, Inc.
(b)	Address of issuer's principal executive offices: 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PENNSYLVANIA, 19073-3269.
Item 2.
(a)	Name of person filing: Infinitum Cayman Master Ltd (Fund) Infinitum Asset Management LLC (Asset Manager) Infinitum Partners GP, LLC (GP)
(b)	Address or principal business office or, if none, residence: 200 East Broward Blvd, Suite 1105 Fort Lauderdale, FL 33301
(c)	Citizenship: Infinitum Cayman Master Ltd, Cayman Islands Infinitum Asset Management LLC, Delaware Infinitum Partners GP, LLC, Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 04272N102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Infinitum Cayman Master Ltd, Cayman Islands 3418923 Infinitum Asset Management LLC, Delaware 3418923 Infinitum Partners GP, LLC, Delaware 3418923
(b)	Percent of class: Infinitum Cayman Master Ltd, Cayman Islands 9.99 Infinitum Asset Management LLC, Delaware 9.99 Infinitum Partners GP, LLC, Delaware 9.99
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Infinitum Cayman Master Ltd, Cayman Islands 3418923 Infinitum Asset Management LLC, Delaware 3418923 Infinitum Partners GP, LLC, Delaware 3418923
	(ii) Shared power to vote or to direct the vote: Infinitum Cayman Master Ltd, Cayman Islands 0 Infinitum Asset Management LLC, Delaware 0 Infinitum Partners GP, LLC, Delaware 0
	(iii) Sole power to dispose or to direct the disposition of: Infinitum Cayman Master Ltd, Cayman Islands 3418923 Infinitum Asset Management LLC, Delaware 3418923 Infinitum Partners GP, LLC, Delaware 3418923
	(iv) Shared power to dispose or to direct the disposition of: Infinitum Cayman Master Ltd, Cayman Islands 0 Infinitum Asset Management LLC, Delaware 0 Infinitum Partners GP, LLC, Delaware 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

INFINITUM ASSET MANAGEMENT, LLC

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	08/13/2025

Infinitum Cayman Master, Ltd. (Fund)

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	08/13/2025

Infinitum Partners GP, LLC

Signature:	John Yetimoglu
Name/Title:	Chief Investment Officer
Date:	08/13/2025

FAQ

How many shares of AVBP does Infinitum report owning?

The filing reports 3,418,923 shares beneficially owned by the Infinitum reporting persons.

What percentage of ArriVent (AVBP) does Infinitum own?

The reported ownership represents 9.99% of ArriVent BioPharma's common stock.

Which entities filed the Schedule 13G for AVBP?

The filers are Infinitum Cayman Master Ltd, Infinitum Asset Management LLC, and Infinitum Partners GP, LLC.

Do the filers have voting or dispositive power over the AVBP shares?

Yes. Each reporting person reports sole voting power and sole dispositive power over the 3,418,923 shares.

Does the filing indicate Infinitum intends to influence control of ArriVent (AVBP)?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.